The FDA has approved Eli Lilly and Co.’s Jaypirca for adult patients with relapsed or refractory CLL or SLL who have previously received therapy with a covalent BTK inhibitor. This expands access to the therapy and converts the accelerated approval for later-line CLL/SLL into a traditional approval. Jaypirca is the first FDA-approved non-covalent BTK inhibitor, offering a novel treatment option for patients. LLY closed Wednesday’s trading session down 1.20%, with the stock continuing to decline in overnight trading. Visit rttnews.com for more health news.

Read more at NASDAQ.: FDA Grants Full Approval To Eli Lilly’s Jaypirca For CLL/SLL